Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.
Eli Lilly's $7.8B Centessa Pharmaceuticals partnership announced in March 2026 continues to anchor the company's pipeline diversification beyond the GLP-1 franchise. Centessa's lead programs include orexin-2 receptor agonist peptides for narcolepsy and other CNS indications, with multiple Phase 1/2 readouts due across 2026-2027. The deal joins Lilly's $7B Kelonia Therapeutics acquisition (in vivo CAR-T platform) and $2.25B Profluent collaboration (AI-designed recombinase genetic medicine) as part of a multi-vertical diversification strategy. The $4.5B Lebanon Indiana LEAP District expansion announced May 6 (for Foundayo and retatrutide manufacturing) signals the GLP-1 franchise remains the cash cow, but the company is actively building optionality outside the obesity-pharmacology lane heading into the 2031 tirzepatide patent cliff.
Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.